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Abstract
Contemporary antiepileptic drugs are ineffective in approximately 30% of the patients.  These 
patients continue to experience seizures and, in many cases, seizures increase in frequency and 
are associated with significant cognitive decline and psychiatric disorders. The delivery of trophic 
factors such as glial cell-derived neurotrophic factor (GDNF) to the CNS has tremendous potential 
for treating a range of diseases including epilepsy. We have recently tested a clinically-validated, 
implantable cell encapsulation system (EC) that delivers high levels of GDNF in a selective, long-
term and stable manner to the epileptogenic area of pilocarpine treated rats.  As such, this 
therapeutic technology platform combines the potency of de novo in situ synthesis of cell-derived 
GDNF with the safety of an implantable, biocompatible, and retrievable medical device. The 
de novo synthetized source of very high levels of GDNF in the brain region of interest proved 
able to significantly reduce generalized seizures frequency, improved cognitive performance and 
normalized anatomical alterations associated with chronic epilepsy.
Introduction
Epilepsy is a devastating neurological condition that affects about 
50 million people of all ages and ethnicities. The affected individual’s 
daily activities, education, employment, and social life is considerably 
disrupted due to the sudden and unpredictable severity of seizures as 
well as the adverse effects of the majority of medications. Even with 
the best pharmacotherapy options, approximately 30% of patients do 
not benefit from drug treatment.  Together with serious cognitive and 
psychiatric co-morbidities, the personal, familial, and societal impact 
of epilepsy is almost impossible to calculate.
Direct, local delivery of therapeutic factors to the disease locus 
may optimize the chances of obtaining efficacy by maximizing 
treatment of the impacted brain region and avoiding the unwanted side-
effects that occur with systemic drug administration.  Here we briefly 
discuss several potential therapeutic proteins of growth factors with 
an emphasis on recent studies using polymer encapsulated cells as the 
delivery system.
Neurotrophic Factors and Epilepsy
Glial cell line-derived neurotrophic factor (GDNF)
In 1993 Lin and colleagues reported the presence of dopaminergic 
neurotrophic activity in conditioned media derived from primary glial 
cells, several cell lines with properties of glia and the characterization 
of the GDNF secreted by a specific (rat B49) glial cell line [1]. Later, 
it was reported that GDNF promoted neurotransmitter release from 
dopaminergic neurons in vivo [2] and in vitro [3], as well as from 
motoneurons in vitro [4]. This was heralded as a breakthrough as 
available treatments were aimed at simply increasing dopaminergic 
transmission while GDNF also prevented neuronal degeneration and 
increased the functional activity of the remaining dopaminergic cells. 
Together these findings made GDNF a potential therapeutic agent for 
various central nervous system diseases, including Parkinson’s disease 
[5], stroke [6] and motoneuron injury [7].
GDNF belongs, together with Neurturin (NRTN), Artemin 
(ARTN) and Persephin (PSPN), to the GDNF-family ligand (GFL) 
which, in turn, is part of the transforming growth factor-β (TGF-β) 
superfamily [8]. Structurally, GDNF presents a typical motif, cystine 
knot, that is involved in protein stabilization and homodimer formation 
and consists of six cysteine residues that are linked together by three 
disulphide bonds. GDNF dimer is readily released from the neural 
cells and binds to GFRα1 receptor. The GDNF–GFRα1 complex then 
interacts with NCAM receptors or with two RET molecules, inducing 
their homodimerization and tyrosine autophosphorylation and initiating 
downstream signaling pathways [9,10]. 
GDNF has also emerged as a possible agent for epilepsy treatment, 
because GDNF family ligand and receptors are expressed in areas 
salient for seizure generation. Specifically, Kokaia and colleagues 
demonstrated a dynamic regulation of GDNF circuits after seizures 
important for the effectiveness of neuroprotective responses. In fact, 
following seizures, GDNF and c-Ret mRNA expression increased 
selectively in the dentate granule cells and hilar neurons, respectively, 
and GFRa-1 mRNA level in both neuron types, which would markedly 
enhance GDNF signaling in this circuit [11]. 
Brain-derived neurotrophic factor (BDNF)
Brain-derived neurotrophic factor (BDNF) is one of the most widely 
distributed and extensively studied neurotrophins in the mammalian 
brain [12]. There is controversy regarding the role of BDNF in 
epileptogenesis. Croll and colleagues showed that overexpression 
of BDNF increased seizure susceptibility [13]. This observation 
was confirmed by a previous study where the status epilepticus (SE) 
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protected against neuronal loss. These findings suggest the possibility 
that the up-regulation of endogenous VEGF after seizures may serve a 
neuroprotective role, and that the VEGF receptor system has potential 
as a novel therapeutic pathway for the development of exogenous 
ligands to prevent cell loss after severe seizures [36]. 
Therapeutic Potential of GDNF and New Delivery 
Systems
GDNF and other neurotrophic factors are candidates for treating 
epilepsy, but their development has been interfered by difficulties in 
achieving stable and targeted delivery of efficacious concentrations 
within the desired brain region [37]. Numerous approaches are under 
investigation for delivering GDNF and other molecules directly to the 
brain including viral vectors, cell transplants and cell encapsulation 
systems (EC). 
Virus-mediated gene therapies 
The direct introduction of different genes inside the brain of 
epileptic patients, each designated to manage electrochemical 
activities that lead to epileptic insults, has potential for the treatment 
of the disease [38]. Yoo and colleagues demonstrated that Adenoviral 
vector-mediated overexpression of GDNF (Ad-GDNF) controls kainic 
acid (KA)-induced hippocampal cell loss and suppresses generalized 
tonic–clonic seizures. Pre-inoculation with Ad-GDNF into the KA-
treated rat hippocampus 7 days before KA injection, suppressed tonic–
clonic convulsions, significantly reduced the numbers of apoptotic cells and 
increased GAD-67 (GABA synthesizing enzyme) and Bcl-2 expression [39].
Similar results have been reported by Kanter-Schlifke and 
colleagues. They reported that recombinant adeno-associated viral 
(rAAV) vector-based GDNF overexpression in the hippocampus 
suppressed generalized seizure activity in kindled and SE-treated 
animal models of Temporal Lobe Epilepsy (TLE). Transduction with 
rAAV-GDNF attenuated seizure severity and convulsive activity 
in both kindled and SE-treated animals. These effects did, however, 
occur despite the fact that epileptogenesis was not affected [40]. Taken 
together, these data suggest that that long-term local increase of GDNF 
levels in the hippocampus could be a possible way of suppressing 
epileptic activity.
Cell-based therapies 
Stem cell grafting-based therapies may be advantageous for treating 
chronic epilepsy thanks to the potential ability of stem cells to replace 
lost neuronal populations and to repair disrupted brain circuitries. 
Waldau and colleagues reported that neural stem cells (NSCs) derived 
from the embryonic medial ganglionic eminence (MGE; MGE-NSC) 
grafted into the hippocampus is an effective approach for suppressing 
spontaneous recurrent motor seizures (SRMS) in chronic TLE. That 
is, epileptic animals exhibited considerable reductions in seizure 
frequency, duration and severity. Furthermore, MGE-NSC grafting 
increased local GABAergic cell populations, increased GDNF 
tissue levels in epileptic animals and restored GDNF expression in 
hippocampal astrocytes [41]. In another studies, transplantation of 
bone marrow mononuclear cells (BMMCs) into epileptic animals has 
been found to be neuroprotective. In particular, Zanirati and colleagues, 
showed that BMMCs transplantation increased levels of several 
neurotrophic factors including GDNF. In fact, in the hippocampus of 
epileptic rats, GDNF mRNA levels were increased at 3 and 7 days post 
transplant while the expression of GDNF protein resulted augmented at 
7 and 14 days post transplant [42].
induced dramatic increase in BDNF expression that persisted for 
several days [14]. Furthermore, increased BDNF correlated with SE-
induced activation of TrkB signaling [15]. A combination of genetic 
approaches showed that PLCγ1 may be the dominant signaling 
effector of SE-induced TrkB activation promoting epileptogenic 
consequences [16]. In contrast, several studies revealed that SE-
induced TrkB activation may promote neuroprotective effects by the 
activation of Shc/Akt signaling pathway, resulting in neuronal survival 
for mammalian neurons in vitro [17,18] and for peripheral sensory 
neurons in vivo [18].  Supporting a positive role for BDNF in seizure 
reductions, we recently reported that EC devices filled with genetically 
modified human cells engineered to release BDNF implanted into the 
hippocampus of pilocarpine-treated rats, decreased the frequency of 
spontaneous seizures by more than 80% [19].
Fibroblast Growth Factor (FGF2)
FGF-2 is a polypeptide composed of 146 amino acids, originally 
purified from the bovine pituitary and named due to its fibroblast growth 
property [20]. FGF-2 reduces brain cellular damage and improves 
functional recovery in experimental models of stroke, epilepsy, and 
traumatic brain and spinal cord injury proving to have neuroprotective 
effects [21]. 
Some studies have shown that FGF-2 overexpression reduces 
seizure induced-cell death and a prolonged administration of FGF-2 
also reduced long-term behavioral deficits [22,23].
Paradiso and colleagues tested the combined action of FGF-2 and 
BDNF using viral vectors to locally supplement the two NTFs post 
epileptogenic damage. In vitro, these vectors increased the proliferation 
of neural progenitors and favored their differentiation into neurons. In 
vivo, the localized delivery of FGF-2/BDNF expressing vectors in 
a lesioned hippocampus, reduced epileptogenesis and spontaneous 
recurring seizures while also increasing local neuronogenesis [24].
Tracolimus (FK506)
FK506, a calcineurin inhibitor and potent immunosuppressant used 
to prevent allograft rejection, exhibits neuroprotective effects in central 
nervous system diseases including epilepsy [25-27]. FK506 prevents 
kainic acid-induced seizures by inhibiting the sprouting of mossy fibers 
in the hippocampus [28] and attenuates pilocarpine-induced seizure and 
neuronal loss in the hippocampus of rats via free radical reduction and 
inhibition of inflammatory factors [29]. Moreover, FK506 treatment 
significantly increased the latency period to seizures and decreased 
the maximal intensity of seizures. FK506 also prevents and restored 
cognitive dysfunction by inhibiting reactive astrogliosis in pilocarpine-
induced status epilepticus rats [30].
Vascular Endothelial Growth Factor (VEGF) 
The vascular endothelial growth factor (VEGF) is a crucial 
regulator of angiogenesis, vascular permeability and it exerts a direct 
trophic effect on neuronal and glial cells in the central nervous system 
[31]. Moreover, it has been implicated in several neurological disorders, 
including epilepsy [32] although it appears to possess both pro- and 
anti-epileptic effects. Cabral and colleagues reported overexpression 
of VEGF-A, VEGF-B, and VEGF-C, their specific and accessory 
receptors in temporal neocortex of pharmacoresistant Temporal Lobe 
Epilepsy (PR-TLE) patients [33]. In contrast, additional studies [34,35], 
particularly those by Nicoletti and colleagues, showed that local 
infusion of Flt-Fc, a VEGF trap, increased neuronal loss after status 
epilepticus, while infusion of exogenous VEGF into the hippocampus 
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Cell encapsulation systems (EC)
Cell encapsulation systems the EC combine the potency of de novo 
in situ synthesis of cell-derived GDNF with the safety of an implantable, 
biocompatible, and retrievable medical device. This system is based 
on implanting trophic factor-secreting cells encapsulated into a 
biocompatible matrix and separated from the host brain tissue by 
a polymer membrane. The membrane pores allow for oxygen and 
nutrients to enter and sustain the encapsulated cells while also allowing 
GDNF to leave the capsule and diffuse into the surrounding brain 
tissue. Furthermore, the pores are immunologically restrictive and 
prevent immunological interference with cell viability [43]. 
As shown below in Figure 1, this system is capable of providing 
long-term sustained delivery to the brain. 
Several studies have addressed the potential of this system as a 
possible tool for the treatment for epilepsy. One of the first studies 
was conducted by Kanter-Schlifke and colleagues reporting that 
encapsulated genetically modified cells could release GDNF over 
at least 5 weeks in the hippocampus while modestly suppressing 
seizures in kindling animals.  More recent studies have repeated and 
extended these studies using human derived ARPE-19 cells modified 
to produce significantly higher levels of GDNF [45,46]. Nanobashvili 
and colleagues used a focal lesion model generated through unilateral 
injections of proconvulsant kainic acid into the hippocampus. Following 
to the latent interval (2 weeks) during which the neural re-arrangements 
leading to spontaneous recurring seizures occur, EC devices loaded 
with GDNF-producing cells were implanted ipsilateral to the lesion. 
Rats implanted with devices showed significant reductions in seizure 
frequency compared to control rats [46].
Our group recently demonstrated not only the efficiency of 
sustained supplementation of GDNF in reducing seizures numbers in 
rat animal models of epilepsy but also that the EC-GDNF treatment 
reversed several cellular and cognitive deficits including impaired 
memory, neurodegeneration, and abnormal neurogenesis. Rats received 
bilateral implants EC-GDNF devices 20 days following the induction 
of status epilepticus (SE). In control rats (i.e. rats implanted with non-
engineered parental cells or empty devices) the number of seizures 
continued unlimited, while in implanted EC-GDNF rats, seizures 
numbers were reduced by approximately 80% within 2 weeks and by 
more than 90% within 3 months. Importantly, these changes in behavior 
occured with improvements in cognitive and anxiety-like behavior 
but without any associated alterations in general physiology (activity, 
weight gain, and circadian rhythmicity) rendering interpretations of 
the benefits specific to the treatment itself and not to any non-specific 
underlying mechanism. Anatomically, GDNF reversed the losses in 
hippocampal volume, reversed the loss of GABAergic parvalbumin-
positive hippocampal cells, prevented the decreased density of NCAM 
receptors and the expression of pRET [37].
Conclusions
In conclusion, for the treatment of chronic diseases like epilepsy, 
it is necessary to use not only a direct and local delivery of therapeutic 
factor but also as long-term treatment such as an EC system to maximize 
treatment of the lesioned brain region avoiding the unwanted side-
effects due to more widespread drug delivery achieved with systemic 
administration. Moreover, the EC treatment can be terminated by 
removal of EC devices from the brain and this latter aspect is important 
safety aspect for possible future clinical trials.
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